Sign In
Buy CMPGY
$32.39
+0.120 (+0.372%)
At Close: Jun 03, 2026
Compass Pathways: Imminent Commercialization Should Provide Further Upside
08:36pm, Thursday, 14'th May 2026
Compass Pathways is nearing an inflection point, with solid Phase III data and government support pointing towards a likely FDA approval. CMPS is positioned to address the large, underserved treatment
CHARLOTTE, N.C.--(BUSINESS WIRE)--University of Kentucky selects Compass Group as its preferred Enterprise Services Partner to align and strengthen services across its campus.
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026
06:30am, Thursday, 14'th May 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
Compass Minerals Announces Participation in Deutsche Bank's 17th Annual Basic Materials Conference in June 2026
04:19pm, Wednesday, 13'th May 2026
OVERLAND PARK, Kan.--(BUSINESS WIRE)--Compass Minerals (NYSE: CMP), a leading global provider of essential minerals, today announced that the company will participate in one-on-one meetings at Deutsch
Compass Pathways shares rise on Q1 results, accelerated FDA review
12:34pm, Wednesday, 13'th May 2026
Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in treatment-resis
Compass Pathways Q1 Earnings Call Highlights
10:08am, Wednesday, 13'th May 2026
Compass Pathways NASDAQ: CMPS said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights
06:30am, Wednesday, 13'th May 2026
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental heal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
04:45pm, Tuesday, 12'th May 2026
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. (“Compass” or the “Company”) (NASDAQ: CMPX). Such invest
Compass Therapeutics to Participate in Upcoming May Investor Events
07:30am, Tuesday, 12'th May 2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t
Compass Group PLC (CMPGY) Q2 2026 Earnings Call Transcript
08:00am, Monday, 11'th May 2026
Compass Group PLC (CMPGY) Q2 2026 Earnings Call Transcript
Compass Group Q2 Earnings Call Highlights
06:09am, Monday, 11'th May 2026
Compass Group LON: CPG raised its full-year profit outlook after reporting what management described as “another very strong half,” with operating profit up 12% and organic revenue growth a little
Compass Minerals International Q2 Earnings Call Highlights
04:05pm, Saturday, 09'th May 2026
Compass Minerals International NYSE: CMP reported improved profitability in its fiscal second quarter despite lower revenue, as management pointed to stronger margins, progress in its Plant Nutrition
Compass Diversified Q1 Earnings Call Highlights
04:05pm, Saturday, 09'th May 2026
Compass Diversified NYSE: CODI reported first-quarter 2026 results that management characterized as a period of execution, highlighted by a divestiture, debt reduction and growth in subsidiary adjuste
Compass is poised to end Brazil's nearly five-year IPO drought
03:12pm, Thursday, 07'th May 2026
Compass Gas e Energia SA, controlled by conglomerate Cosan SA , is set to price its initial public offering on Thursday, breaking a nearly five-year IPO drought on Brazil's B3 stock exchange cau
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX
10:00am, Thursday, 07'th May 2026
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Compass Therapeutics, Inc. ("Compass" or the "Company") (NASDAQ: CMPX). Such investors are advis
